About us
A local drug delivery approach for patients with no treatment options
About us
PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital — built around a small team of passionate experts in pharmaceutical and medical sciences, drug delivery and biomaterials design.
Local therapeutic implants
Innovative development of injectable, biodegradable micro-implants — tailored to deliver drugs at the precise site of the disease.
High unmet medical needs
Expertise focused on drug delivery for rheumatology and hematology indications.
A portfolio of early projects in long-neglected areas: gout flare (ARTHRELIS program) and bone marrow transplantation enhancement (ENGRAFTIS program).
Key figures
Patented innovation, tangible
momentum
PROGRAMS
2
Programs in rheumatology and hematology
ARTHRELIS
1st
dual-action local treatment for refractory gout flares patients
ENGRAFTIS
1st
local therapy improving bone marrow graft
FOUNDED
2019
Paris-based, backed by
Truffle Capital
Our management team
Anaïs Vissian
Director of
Clinical Operations
Director of Pharmaceutical
Development
Farah Marzouki, EngD, MSc
CEO
Gauthier Pouliquen, PhD
Director of R&D
Charles Sanson, PhD
CFO
Vincent Dagommer
Our Board of Directors
François Romaneix
Chairman
Tom Tice, PhD
Pr. Karine Lacombe
MD, PhD
Pr. Philippe Leboulch,
MD
Philippe Pouletty, MD
Isabelle Buckle, PhD
Pr. Daniel Hayoz, MD
Our Scientific Advisory Board
Pr. Daniel Hayoz, MD
Pr. Philippe Leboulch,
MD
Pr. Geraldine McCarthy,
MD
Pr. Alain Fischer, MD
President
Pr. Tuhina Neogi,
MD, PhD
Pr. Marie-Christophe
Boissier, MD, PhD
Pr. Tristan Pascart,
MD, PhD
With the support of
